Antiulcer activity of ethanolic leaf extract of Capparis zeylanica against chemically induced ulcers

Background Peptic ulcer is the term which refers to acid peptic injury of the digestive tract, and it results in mucosal break reaching the submucosa. Leaves of Capparis zeylanica are used as counterirritant, rubefacient, as a cataplasm in piles, boils and swellings. The objective of the present study was to evaluate the antiulcer activity of C. zeylanica ethanolic extract against chemically induced ulcers. The leaves were extracted with ethanol (50%) as solvent using hot perforation method. The extract was evaluated against acute and chronic ulcer models. Further, extract was evaluated for gastric autopsy of animals infected with Helicobacter pylori bacteria. The genes of rats were evaluated by gel electrophoresis method. Morphology of stomach was also studied after treatment with plant extract. Results Results exhibited that the area of ulcer was significantly reduced in both acute [naproxen-induced ulcer model (3.62 mm2), histamine-induced ulcer model (3.2 mm2) and ethanol-induced ulcer model (106.4 mm2)] and chronic [chronic naproxen-induced ulcer model (2.14 mm2), chronic histamine-induced ulcer model (0.16 mm2)]. The animals of naproxen-induced ulcer infected with H. pylori showed 91.48% reduction of ulcer area on 9th week after treatment with C. zeylanica extract (360 mg/kg). The rapid urease test and DNA observation revealed that no infection was present from 4th week after treatment with C. zeylanica extract (480 mg/kg). Morphological studies showed less conspicuous petechial marks and hemorrhages in stomach tissues after treatment with test drugs. Histopathological study revealed that C. zeylanica extract reduced stomach damages and eradicated H. pylori infections. Conclusion It can be concluded from the study that C. zeylanica possess antiulcer and anti-helicobacter activities.

Profile of the Change in Depression during Proton-Pump Inhibitor Therapy in Patients with Gastroesophageal Reflux Disease: Influence of the Mucosal Break

Given the frequent concomitance between depression and gastroesophageal reflux disease (GERD), it is important to evaluate the change of depression in patients with GERD, especially considering the presence of esophageal mucosal breaks (MB). This study aimed to examine the change in the levels of depression in patients with GERD during proton-pump inhibitors (PPI) therapy. We designed a prospective cohort study to explore the profile of the alteration in depression with respect to the impact of esophageal MB. This study recruited 172 eligible patients with GERD between February 2016 and May 2018. The change in depression was defined as the difference between the respective Taiwanese Depression Questionnaire (TDQ) scores obtained at baseline and after PPI therapy. Multivariate linear regression models were used to estimate the factors associated with the change in depression. The results revealed statistically significant improvements in the TDQ score (mean score: baseline = 13.2, after PPI therapy = 10.9, p < 0.01, Cohen’s d = 0.30) during PPI therapy for GERD. Moreover, the MB was an independent variable associated with changes in the TDQ score [B = 3.31, 95% confidence interval (CI): (1.12, 5.51), p < 0.01] and the improvement in depression [odds ratio = 0.38, 95% CI: (0.17, 0.86), p = 0.02]. Our findings revealed that depressive symptoms improved slightly following PPI therapy. Moreover, MB was an unfavorable prognostic factor for the improvement in depression.

Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn’s Disease

Background and aim Objective and more rigorous therapeutic outcomes are emerging as novel targets in Crohn’s disease (CD). We investigated the association between maintenance serum infliximab trough concentrations and biochemical, endoscopic, or histologic remission in CD. Methods This retrospective multicenter study involved consecutive CD patients treated with infliximab who had a serum C-reactive protein (CRP) measured within 1 week or endoscopic evaluation within 12 weeks of therapeutic drug monitoring between January 2010 and June 2016. Biochemical remission was defined as a normal CRP (≤5 mg/L). Endoscopic remission was defined as absence of any mucosal break (ulceration or erosion) or for patients with an ileocolonic resection, a Rutgeerts score of ≤i1. Histologic remission was defined as absence of active inflammation. Results Seventy-one CRP levels and 96 colonoscopies from 110 CD patients were evaluated. Based on ROC analyses, infliximab concentration thresholds of 2.2, 9.7, and 9.8 μg/mL were found to be related with biochemical, endoscopic, and histologic remission, respectively. Multiple logistic regression analyses identified infliximab concentration ≥2.2 (OR 6.4; 95% CI, 1.5–27.1; P = 0.011), ≥9.7 (OR 3.6; 95% CI, 1.4–9; P = 0.006) and ≥9.8 μg/mL (OR 3.2; 95% CI, 1.3–7.9; P = 0.011) as variables independently associated with biochemical, endoscopic, and histologic remission, respectively. Conclusions This study showed that higher maintenance infliximab trough concentrations are associated with more favorable rates of biochemical, endoscopic, or histologic remission in CD patients and that infliximab concentrations may differ based on the treatment goal.